Relationship between vedolizumab serum concentrations in the induction phase and early and sustained response in the first year of treatment in patients with ulcerative colitis.

Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria
PMID:

Abstract

OBJECTIVE: Evidence on the usefulness of proactive monitoring of vedolizumab serum concentrations during the induction phase of treatment is limited. The objective of our study was to evaluate the effectiveness of measuring such concentrations during this phase in predicting response to  treatment in patients with ulcerative colitis with a view to determining whether  patients would benefit from early monitoring of  edolizumab serum concentrations.

Authors

  • José Germán Sánchez-Hernández
    Servicio de Farmacia, Hospital Universitario de Salamanca-IBSAL, Salamanca. Spain.. jgermansanchez@saludcastillayleon.es.
  • Noemí Rebollo
    Servicio de Farmacia, Hospital Universitario de Salamanca-IBSAL, Salamanca. Spain.. noemirebollo@gmail.com.
  • Fernando Muñoz
    Servicio de Aparato Digestivo, Hospital Universitario de Salamanca-IBSAL, Salamanca. Spain.. jgermansh@gmail.com.
  • Nuria Padullés-Zamora
    Servicio de Farmacia, Hospital Universitario de Bellvitge-IDIBELL, Barcelona. Spain.. nuria.padulles@gmail.com.
  • Marta Miarons
    Servicio de Farmacia, Hospital Universitario de Vall'Hebron, Barcelona. Spain.. mmiarons@vhebron.net.
  • Nerea Martín Gutiérrez
    Servicio de Farmacia, Hospital Universitario de Salamanca-IBSAL, Salamanca. Spain.. noemirebollo@gmail.com.
  • Marcos Martín Gil
    Servicio de Farmacia, Hospital Universitario de Salamanca-IBSAL, Salamanca. Spain.. noemirebollo@gmail.com.
  • María José Otero
    Servicio de Farmacia, Hospital Universitario de Salamanca-IBSAL, Salamanca. Spain.. noemirebollo@gmail.com.